TREM2 stabilizing antibodies
Grant
US12595305B2
Kind: B2
Apr 07, 2026
Assignee
Novartis AG
Inventors
Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
Abstract
The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
CPC Classifications
C07K 16/2803
C07K 2317/565
C12N 15/70
Filing Date
2022-09-23
Application No.
17934795
Claims
10